Sittivarakul Wantanee, Benjhawaleemas Thanyapat, Aui-Aree Nipat, Jirarattanasopa Pichai, Liabsuetrakul Tippawan
a Department of Ophthalmology, Faculty of Medicine , Prince of Songkla University , Hat Yai , Thailand and.
b Epidemiology Unit, Faculty of Medicine , Prince of Songkla University , Hat Yai , Thailand.
Ocul Immunol Inflamm. 2016 Oct;24(5):530-6. doi: 10.3109/09273948.2015.1032307. Epub 2015 Aug 10.
To calculate the incidence of, and to identify the risk factors for developing contralateral eye involvement among patients with AIDS and unilateral cytomegalovirus retinitis (CMV retinitis), who were treated, in the era of highly-active antiretroviral therapy (HAART), with repetitive intravitreal ganciclovir injections.
The clinical records of 119 patients were included. The main outcome measurement was the occurrence of contralateral eye involvement.
Over a mean follow-up period of 1.6 years, the overall incidence rate of contralateral involvement was 0.17/person-year. The cumulative incidence of contralateral involvement at 6 months and 1 year was 23.8% and 28.4%, respectively. Receiving HAART at the visit before the event was associated with a decreased risk of developing contralateral retinitis (hazard ratio [HR] = 0.26, P = 0.002).
The use of HAART, associated with subsequent immune recovery, significantly reduced the incidence of contralateral eye involvement by approximately 75% among patients in our setting.
计算在高效抗逆转录病毒治疗（HAART）时代，接受重复玻璃体内注射更昔洛韦治疗的艾滋病合并单侧巨细胞病毒性视网膜炎（CMV视网膜炎）患者对侧眼受累的发生率，并确定其危险因素。
纳入119例患者的临床记录。主要观察指标为对侧眼受累的发生情况。
平均随访1.6年，对侧受累的总体发生率为0.17/人年。6个月和1年时对侧受累的累积发生率分别为23.8%和28.4%。事件发生前就诊时接受HAART与对侧视网膜炎发生风险降低相关（风险比[HR]=0.26，P=0.002）。
在我们的研究中，HAART的使用与随后的免疫恢复相关，显著降低了对侧眼受累的发生率，降低幅度约为75%。
